Proteomics International Laboratories Ltd (AU:PIQ) — Market Cap & Net Worth
Market Cap & Net Worth: Proteomics International Laboratories Ltd (PIQ)
Proteomics International Laboratories Ltd (AU:PIQ) has a market capitalization of $13.44 Million (AU$19.00 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26299 globally and #1212 in its home market, demonstrating a -8.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Proteomics International Laboratories Ltd's stock price AU$0.12 by its total outstanding shares 165183999 (165.18 Million). Review PIQ total debt and obligations to assess the company's total debt and financial obligations.
Proteomics International Laboratories Ltd Market Cap History: 2015 to 2026
Proteomics International Laboratories Ltd's market capitalization history from 2015 to 2026. Data shows change from $33.31 Million to $13.44 Million (-8.87% CAGR).
Proteomics International Laboratories Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Proteomics International Laboratories Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
79.71x
Proteomics International Laboratories Ltd's market cap is 79.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $29.22 Million | $816.85K | -$1.33 Million | 35.77x | N/A |
| 2017 | $31.56 Million | $925.36K | -$916.48K | 34.10x | N/A |
| 2018 | $44.41 Million | $1.18 Million | -$1.44 Million | 37.75x | N/A |
| 2019 | $31.56 Million | $1.47 Million | -$2.08 Million | 21.50x | N/A |
| 2020 | $92.92 Million | $1.42 Million | -$1.74 Million | 65.29x | N/A |
| 2021 | $142.01 Million | $1.31 Million | -$2.86 Million | 108.33x | N/A |
| 2022 | $111.03 Million | $1.49 Million | -$4.97 Million | 74.55x | N/A |
| 2023 | $104.61 Million | $730.34K | -$6.23 Million | 143.23x | N/A |
| 2024 | $93.50 Million | $892.14K | -$6.38 Million | 104.81x | N/A |
| 2025 | $76.56 Million | $960.39K | -$8.11 Million | 79.71x | N/A |
Competitor Companies of PIQ by Market Capitalization
Companies near Proteomics International Laboratories Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Proteomics International Laboratories Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Proteomics International Laboratories Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Proteomics International Laboratories Ltd's market cap moved from $33.31 Million to $ 13.44 Million, with a yearly change of -8.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$13.44 Million | -82.44% |
| 2025 | AU$76.56 Million | -18.12% |
| 2024 | AU$93.50 Million | -10.61% |
| 2023 | AU$104.61 Million | -5.79% |
| 2022 | AU$111.03 Million | -21.81% |
| 2021 | AU$142.01 Million | +52.83% |
| 2020 | AU$92.92 Million | +194.44% |
| 2019 | AU$31.56 Million | -28.95% |
| 2018 | AU$44.41 Million | +40.74% |
| 2017 | AU$31.56 Million | +8.00% |
| 2016 | AU$29.22 Million | -12.28% |
| 2015 | AU$33.31 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Proteomics International Laboratories Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.44 Million USD |
| MoneyControl | $13.44 Million USD |
| MarketWatch | $13.44 Million USD |
| marketcap.company | $13.44 Million USD |
| Reuters | $13.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more